EXOZ - Invizyne Technologies Debt to Book Capitalization Ratio

Graphic logo of Invizyne Technologies (EXOZ)

This chart's stock quotes serve as an indicator for the eXoZymes Inc (EXOZ) business, which relies on access to global resources and overcoming geopolitical challenges while management scales laboratory developments to industrial volumes, which constitutes 0.32. Meanwhile, eXoZymes Inc (EXOZ) is cementing its status as a leader in synthetic biology by creating safe and environmentally friendly methods for obtaining complex compounds.

EXOZ (Invizyne) Debt to Book Value history from 02/13/2025 to 10/28/2026

Invizyne Technologies (EXOZ) - metric breakdowns and financial figures

- price and consensus price forecast:
Stock Price eXoZymes Inc|EXOZ - Analyst Consensus Forecast
- market capitalization data:
Market Value Invizyne|EXOZ - Value Adjusted for Debt and Cash
- book capitalization data:
Net Assets per Single Share eXoZymes|EXOZ - Company Net Assets|Market Capitalization to Book Value Ratio invizyne.com|EXOZ - Company Total Assets
- debt and liquidity data:
Total Debt to Equity Ratio eXoZymes Inc|EXOZ - Long-Term Debt to Capital Coefficient|Short-Term Debt to Equity Invizyne Technologies, Inc.|EXOZ - Company Cumulative Debt|Debt to Book Value Invizyne
Analysis of all company metrics:EXOZ eXoZymes Inc
Core merchandise of Invizyne Technologies, Inc.

Investors utilize this ratio to assess financial stability and determine the debt load ceiling prior to a potential asset takeover. For eXoZymes Inc (EXOZ), a startup operating within the favorable US jurisdiction on green technologies, the debt-to-capitalization ratio demonstrates a balance between capital security and credit leverage efficiency, characterizing the company as a low-risk growth instrument.

Competitors of eXoZymes Inc

Debts to Book Capitalization HLN (Haleon plc)|kenvue.com - Debts to Book Capitalization|Debt to Book Capitalization Ratio Verona Pharma (VRNA)|MENS: Debt to Net Assets Ratio|LGND (Ligand Pharma) - Debt to Book Capitalization Ratio|Amneal Corp (AMRX) - Debt to Book Value|PRGO (Perrigo Company plc) - Debts to Book Capitalization|Debts to Book Capitalization alvotech.com (ALVO)|Liquidia (LQDA) - Debt to Book Value|Debt to Net Assets Ratio GLPG (Galapagos N.V.)|ANIP: Debt to Book Capitalization Ratio|MNKD - Debts to Book Value|Debt to Book Value Amphastar Pharmaceuticals AMPH|PCRX - Debt to Book Capital|Debts to Book Capitalization ARS Pharmaceuticals, Inc. SPRY|Theravance Biopharma Inc (TBPH) - Debt to Net Assets Ratio|Debts to Book Capitalization AQST (Aquestive Pharma)|Debts to Book Value SCPH|Tectonic Therapeutic, Inc. (TECX) - Debt to Book Capitalization Ratio|Debt to Net Assets Ratio tonixpharma.com (TNXP)|SXTC: Debts to Book Capitalization|EPRX - Debts to Book Value|BioHarvest (BHST) - Debt to Book Value|ORMP: Debt to Book Value Ratio|Debt to Book Capitalization Ratio ENTX|Debts to Book Value ipatherapeutics.com|Debt to Book Value ABVC BioPharma, Inc. ABVC|Debts to Book Capitalization Ratio Cumberland Pharmaceuticals Inc (CPIX)|Quantum BioPharma Limited - Debt to Book Value|Debts to Book Value FGEN (FibroGen Corporation)|Telomir Pharmaceuticals - Debt to Book Capitalization Ratio|Debt to Book Value Rani Therapeutics Holdings RANI|SNYR (Synergy CHC Corporation) - Debts to Book Capitalization|RLYB: Debts to Book Value|lexariabioscience.com - Debt to Book Capitalization Ratio|Debts to Net Assets Pulmatrix Corporation|PTHL - Debt to Book Value|Debt to Net Assets Ratio Aptorum|LYRA (Lyra Therapeutics) - Debts to Book Capitalization|Debts to Net Assets IBO (Impact BioMedical, Inc.)|TNFA - Debt to Book Capitalization Ratio|Debt to Book Value Ratio cbdMD Inc. YCBD|PRFX: Debts to Book Capitalization|CYTO - Debt to Book Value|Debts to Book Capitalization LIPO|Debts to Book Value OptiNose Inc|Debt to Book Value Pieris (PIRS)|Debt to Book Value Ratio PROC|Petros Pharmaceuticals - Debt to Book Capitalization Ratio|Debts to Book Value qlsyy.net QLI|ACELYRIN (SLRN) - Debt to Book Value|TFF Pharmaceuticals Inc. - Debts to Book Capitalization Ratio